{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:59:30Z","timestamp":1792609170788,"version":"4.5.0"},"reference-count":47,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,12,22]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The prognostic relevance of additional cytogenetic findings at diagnosis of chronic myeloid leukemia (CML) is unclear. The impact of additional cytogenetic findings at diagnosis on time to complete cytogenetic (CCR) and major molecular remission (MMR) and progression-free (PFS) and overall survival (OS) was analyzed using data from 1151 Philadelphia chromosome\u2013positive (Ph+) CML patients randomized to the German CML Study IV. At diagnosis, 1003 of 1151 patients (87%) had standard t(9;22)(q34;q11) only, 69 patients (6.0%) had variant t(v;22), and 79 (6.9%) additional cytogenetic aberrations (ACAs). Of these, 38 patients (3.3%) lacked the Y chromosome (\u2212Y) and 41 patients (3.6%) had ACAs except \u2212Y; 16 of these (1.4%) were major route (second Philadelphia [Ph] chromosome, trisomy 8, isochromosome 17q, or trisomy 19) and 25 minor route (all other) ACAs. After a median observation time of 5.3 years for patients with t(9;22), t(v;22), \u2212Y, minor- and major-route ACAs, the 5-year PFS was 90%, 81%, 88%, 96%, and 50%, and the 5-year OS was 92%, 87%, 91%, 96%, and 53%, respectively. In patients with major-route ACAs, the times to CCR and MMR were longer and PFS and OS were shorter (P &lt; .001) than in patients with standard t(9;22). We conclude that major-route ACAs at diagnosis are associated with a negative impact on survival and signify progression to the accelerated phase and blast crisis.<\/jats:p>","DOI":"10.1182\/blood-2011-08-373902","type":"journal-article","created":{"date-parts":[[2011,10,29]],"date-time":"2011-10-29T02:23:41Z","timestamp":1319855021000},"page":"6760-6768","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":236,"title":["Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV"],"prefix":"10.1182","volume":"118","author":[{"given":"Alice","family":"Fabarius","sequence":"first","affiliation":[{"name":"III. Medizinische Universit\u00e4tsklinik, Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Leitner","sequence":"additional","affiliation":[{"name":"III. Medizinische Universit\u00e4tsklinik, Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[{"name":"Abteilung f\u00fcr H\u00e4matologie\/Onkologie, Universit\u00e4tsklinikum Jena, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin C.","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"III. Medizinische Universit\u00e4tsklinik, Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Hanfstein","sequence":"additional","affiliation":[{"name":"III. Medizinische Universit\u00e4tsklinik, Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Haferlach","sequence":"additional","affiliation":[{"name":"MLL M\u00fcnchner Leuk\u00e4mielabor GmbH, M\u00fcnchen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"G\u00f6hring","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Zell-und Molekularpathologie, Medizinische Hochschule Hannover, Hannover, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Schlegelberger","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Zell-und Molekularpathologie, Medizinische Hochschule Hannover, Hannover, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Jotterand","sequence":"additional","affiliation":[{"name":"Service de g\u00e9n\u00e9tique m\u00e9dicale, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Reiter","sequence":"additional","affiliation":[{"name":"III. Medizinische Universit\u00e4tsklinik, Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Jung-Munkwitz","sequence":"additional","affiliation":[{"name":"III. Medizinische Universit\u00e4tsklinik, Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Proetel","sequence":"additional","affiliation":[{"name":"III. Medizinische Universit\u00e4tsklinik, Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Schwaab","sequence":"additional","affiliation":[{"name":"III. Medizinische Universit\u00e4tsklinik, Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf-Karsten","family":"Hofmann","sequence":"additional","affiliation":[{"name":"III. Medizinische Universit\u00e4tsklinik, Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Schubert","sequence":"additional","affiliation":[{"name":"Abteilung f\u00fcr H\u00e4matologie-Onkologie, Evangelisches Krankenhaus Hamm, Hamm, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik II, Universit\u00e4tsklinikum W\u00fcrzburg, W\u00fcrzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony D.","family":"Ho","sequence":"additional","affiliation":[{"name":"Abteilung Innere Medizin V, Medizinische Klinik, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Falge","sequence":"additional","affiliation":[{"name":"Medizinische Klinik 5, Klinikum N\u00fcrnberg Nord, N\u00fcrnberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar","family":"Kanz","sequence":"additional","affiliation":[{"name":"Medizinische Klinik, Abteilung II, Universit\u00e4tsklinikum T\u00fcbingen, T\u00fcbingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Neubauer","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin, Schwerpunkt H\u00e4matologie, Onkologie und Immunologie, Universit\u00e4tsklinikum Marburg, Marburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kneba","sequence":"additional","affiliation":[{"name":"II. Medizinische Klinik und Poliklinik im St\u00e4dtischen Krankenhaus, Universit\u00e4tsklinikum Schleswig-Holstein, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Stegelmann","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, Universit\u00e4tsklinikum Ulm, Ulm, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pfreundschuh","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin I, Universit\u00e4tsklinikum des Saarlandes, Homburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelius F.","family":"Waller","sequence":"additional","affiliation":[{"name":"Abteilung Innere Medizin I, Universit\u00e4tsklinikum Freiburg, Freiburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Spiekermann","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik III, Klinikum der Universit\u00e4t M\u00fcnchen-Grosshadern, M\u00fcnchen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela M.","family":"Baerlocher","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinik f\u00fcr H\u00e4matologie und h\u00e4matologisches Zentrallabor, Universit\u00e4tsspital Bern, Bern, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lauseker","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE), Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Pfirrmann","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE), Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Hasford","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE), Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Saussele","sequence":"additional","affiliation":[{"name":"III. Medizinische Universit\u00e4tsklinik, Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Hehlmann","sequence":"additional","affiliation":[{"name":"III. Medizinische Universit\u00e4tsklinik, Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Schweizerische Arbeitsgemeinschaft f\u00fcr Klinische Krebsforschung (SAKK) and the German CML Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5405","key":"2019111807220572900_B1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"issue":"6","key":"2019111807220572900_B2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer.","volume":"7","author":"Melo","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"9584","key":"2019111807220572900_B3","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Chronic myeloid leukaemia.","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"issue":"4","key":"2019111807220572900_B4","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1080\/03093640701859089","article-title":"BCR\/ABL, DNA damage and DNA repair: Implications for new treatment concepts.","volume":"49","author":"Skorski","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2019111807220572900_B5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/ijc.2910180105","article-title":"Non-random karyotypic evolution in chronic myeloid leukemia.","volume":"18","author":"Mitelman","year":"1976","journal-title":"Int J Cancer"},{"issue":"s1","key":"2019111807220572900_B6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3109\/10428199309047856","article-title":"The Cytogenetic Scenario of Chronic Myeloid Leukemia.","volume":"11","author":"Mitelman","year":"1993","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2019111807220572900_B7","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJM199403243301204","article-title":"Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia.","volume":"330","author":"Italian Cooperative Study Group On Chronic Myeloid Leukemia","year":"1994","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111807220572900_B8","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"2019111807220572900_B9","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2002-09-2790","article-title":"Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"issue":"2","key":"2019111807220572900_B10","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/sj.leu.2402813","article-title":"Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate.","volume":"17","author":"Schoch","year":"2003","journal-title":"Leukemia"},{"issue":"11","key":"2019111807220572900_B11","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/cncr.25015","article-title":"Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.","volume":"116","author":"Verma","year":"2010","journal-title":"Cancer"},{"issue":"3","key":"2019111807220572900_B12","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/leu.2009.222","article-title":"Similar patterns of chromosome abnormalities in CML occur in addition to the Philadelphia chromosome with or without tyrosine kinase inhibitor treatment.","volume":"24","author":"Haferlach","year":"2010","journal-title":"Leukemia"},{"issue":"5","key":"2019111807220572900_B13","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2002-03-0777","article-title":"The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML.","volume":"100","author":"O'Dwyer","year":"2002","journal-title":"Blood"},{"issue":"2","key":"2019111807220572900_B14","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood-2003-02-0371","article-title":"Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate.","volume":"103","author":"O'Dwyer","year":"2004","journal-title":"Blood"},{"issue":"2","key":"2019111807220572900_B15","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/sj.leu.2402813","article-title":"Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate.","volume":"17","author":"Schoch","year":"2003","journal-title":"Leukemia"},{"issue":"35","key":"2019111807220572900_B16","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111807220572900_B17","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1182\/blood.V72.1.294.294","article-title":"Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia.","volume":"72","author":"Sokal","year":"1988","journal-title":"Blood"},{"issue":"6","key":"2019111807220572900_B18","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1182\/blood.V66.6.1326.1326","article-title":"Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival.","volume":"66","author":"Kantarjian","year":"1985","journal-title":"Blood"},{"issue":"1","key":"2019111807220572900_B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0002-9343(90)90119-X","article-title":"Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia.","volume":"88","author":"Kantarjian","year":"1990","journal-title":"Am J Med"},{"issue":"1","key":"2019111807220572900_B20","first-page":"143","article-title":"Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: A Cancer and Leukemia Group B study.","volume":"25","author":"Farag","year":"2004","journal-title":"Int J Oncol"},{"issue":"4","key":"2019111807220572900_B21","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/gcc.10183","article-title":"Genomic deletions on other chromosomes involved in variant t(9;22) chronic myeloid leukemia cases.","volume":"36","author":"Albano","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"issue":"2","key":"2019111807220572900_B22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2141.2004.04899.x","article-title":"Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome.","volume":"125","author":"El-Zimaity","year":"2004","journal-title":"Br J Haematol"},{"issue":"25","key":"2019111807220572900_B23","doi-asserted-by":"crossref","first-page":"6793","DOI":"10.1182\/blood-2011-01-328294","article-title":"Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis.","volume":"117","author":"Marzocchi","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111807220572900_B24","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/sj.leu.2403162","article-title":"A potential role for PRDM12 in the pathogenesis of chronic myeloid leukaemia with derivative chromosome 9 deletion.","volume":"18","author":"Reid","year":"2004","journal-title":"Leukemia"},{"issue":"16","key":"2019111807220572900_B25","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1200\/JCO.2009.26.7963","article-title":"Deletions of the Derivative Chromosome 9 Do Not Influence the Response and the Outcome of Chronic Myeloid Leukemia in Early Chronic Phase Treated With Imatinib Mesylate: GIMEMA CML Working Party Analysis.","volume":"28","author":"Castagnetti","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111807220572900_B26","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3324\/haematol.2009.019109","article-title":"Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy.","volume":"95","author":"Lippert","year":"2010","journal-title":"Haematologica"},{"issue":"12","key":"2019111807220572900_B27","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800 mg\/d versus 400 mg\/d versus 400 mg\/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia.","volume":"29","author":"Hehlmann","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111807220572900_B28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.leu.2402329","article-title":"Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases.","volume":"16","author":"Schoch","year":"2002","journal-title":"Leukemia"},{"key":"2019111807220572900_B29","volume-title":"ISCN 2009. An International System for Human Cytogenetic Nomenclature","author":"Shaffer","year":"2009"},{"issue":"2","key":"2019111807220572900_B30","first-page":"302","article-title":"Pericentric inversion 9: Incidence and clinical significance.","volume":"24","author":"Teo","year":"1995","journal-title":"Ann Acad Med Singapore"},{"issue":"12","key":"2019111807220572900_B31","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1093\/hmg\/8.12.2205","article-title":"The origin of the extra Y chromosome in males with a 47,XYY karyotype.","volume":"8","author":"Robinson","year":"1999","journal-title":"Hum Mol Genet"},{"issue":"24","key":"2019111807220572900_B32","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1182\/blood-2009-07-229864","article-title":"Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP.","volume":"114","author":"Testoni","year":"2009","journal-title":"Blood"},{"issue":"11","key":"2019111807220572900_B33","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/sj.leu.2401566","article-title":"Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR.","volume":"13","author":"Emig","year":"1999","journal-title":"Leukemia"},{"issue":"1","key":"2019111807220572900_B34","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/sj.leu.2404983","article-title":"Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories.","volume":"22","author":"M\u00fcller","year":"2008","journal-title":"Leukemia"},{"issue":"11","key":"2019111807220572900_B35","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/leu.2009.168","article-title":"Harmonization of molecular monitoring of CML therapy in Europe.","volume":"23","author":"M\u00fcller","year":"2009","journal-title":"Leukemia"},{"issue":"6","key":"2019111807220572900_B36","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"issue":"9","key":"2019111807220572900_B37","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/leu.2011.116","article-title":"Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia.","volume":"25","author":"Pfirrmann","year":"2011","journal-title":"Leukemia"},{"issue":"3","key":"2019111807220572900_B38","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2019111807220572900_B39","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/cncr.21756","article-title":"Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal.","volume":"106","author":"Cortes","year":"2006","journal-title":"Cancer"},{"issue":"1","key":"2019111807220572900_B40","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1200\/JCO.1996.14.1.196","article-title":"Significance of cytogenetic clonal evolution in chronic myelogenous leukemia.","volume":"14","author":"Majlis","year":"1996","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111807220572900_B41","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1182\/blood-2002-09-2763","article-title":"Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions.","volume":"102","author":"Huntly","year":"2003","journal-title":"Blood"},{"issue":"6","key":"2019111807220572900_B42","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ccr.2004.10.015","article-title":"MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors.","volume":"6","author":"Huntly","year":"2004","journal-title":"Cancer Cell"},{"issue":"4","key":"2019111807220572900_B43","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1182\/blood-2007-02-074252","article-title":"Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia.","volume":"110","author":"Kreil","year":"2007","journal-title":"Blood"},{"issue":"10","key":"2019111807220572900_B44","doi-asserted-by":"crossref","first-page":"6778","DOI":"10.1073\/pnas.251670699","article-title":"Specific aneusomies in Chinese hamster cells at different stages of neoplastic transformation, initiated by nitrosomethylurea.","volume":"99","author":"Fabarius","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2019111807220572900_B45","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cancergencyto.2007.10.006","article-title":"Specific clones of spontaneously evolving karyotypes generate individuality of cancers.","volume":"180","author":"Fabarius","year":"2008","journal-title":"Cancer Genet Cytogenet"},{"issue":"13","key":"2019111807220572900_B46","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.4161\/cc.10.13.16352","article-title":"Is carcinogenesis a form of speciation?","volume":"10","author":"Duesberg","year":"2011","journal-title":"Cell Cycle"},{"issue":"10","key":"2019111807220572900_B47","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","article-title":"Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.","volume":"115","author":"Saussele","year":"2010","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/26\/6760\/1344662\/zh805211006760.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/26\/6760\/1344662\/zh805211006760.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T07:05:31Z","timestamp":1713078331000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/26\/6760\/29438\/Impact-of-additional-cytogenetic-aberrations-at"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,22]]},"references-count":47,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2011,12,22]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-08-373902","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,22]]}}}